CN112218866A - 螺-内酰胺nmda受体调节剂及其用途 - Google Patents

螺-内酰胺nmda受体调节剂及其用途 Download PDF

Info

Publication number
CN112218866A
CN112218866A CN201980018351.6A CN201980018351A CN112218866A CN 112218866 A CN112218866 A CN 112218866A CN 201980018351 A CN201980018351 A CN 201980018351A CN 112218866 A CN112218866 A CN 112218866A
Authority
CN
China
Prior art keywords
compound
alkyl
optionally substituted
phenyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980018351.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·卡恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuanyi Biotechnology Hong Kong Ltd
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of CN112218866A publication Critical patent/CN112218866A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980018351.6A 2018-01-31 2019-01-31 螺-内酰胺nmda受体调节剂及其用途 Pending CN112218866A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862624218P 2018-01-31 2018-01-31
US62/624,218 2018-01-31
US201862718107P 2018-08-13 2018-08-13
US62/718,107 2018-08-13
PCT/US2019/016098 WO2019152678A1 (en) 2018-01-31 2019-01-31 Spiro-lactam nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
CN112218866A true CN112218866A (zh) 2021-01-12

Family

ID=65494516

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018351.6A Pending CN112218866A (zh) 2018-01-31 2019-01-31 螺-内酰胺nmda受体调节剂及其用途

Country Status (15)

Country Link
US (1) US20210047324A1 (https=)
EP (1) EP3746442A1 (https=)
JP (2) JP2021512109A (https=)
KR (1) KR20200115610A (https=)
CN (1) CN112218866A (https=)
AU (1) AU2019215049A1 (https=)
BR (1) BR112020015666A2 (https=)
CA (1) CA3089559A1 (https=)
CL (1) CL2020001990A1 (https=)
IL (1) IL276330A (https=)
MX (1) MX2020008106A (https=)
PE (1) PE20211455A1 (https=)
PH (1) PH12020551140A1 (https=)
SG (1) SG11202007251XA (https=)
WO (1) WO2019152678A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032649B1 (ru) 2013-01-29 2019-06-28 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2024054919A1 (en) * 2022-09-08 2024-03-14 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
US20250115551A1 (en) * 2023-10-03 2025-04-10 Revolution Medicines, Inc. Synthesis of ras inhibitors

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186883A (zh) * 2008-09-18 2011-09-14 诺雷克斯股份有限公司 Nmda受体调节剂和其用途
CN102933226A (zh) * 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
CN105026401A (zh) * 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105229010A (zh) * 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105229011A (zh) * 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105308049A (zh) * 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105408336A (zh) * 2013-01-29 2016-03-16 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2017201285A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
HUE049481T2 (hu) * 2015-04-03 2020-09-28 Recurium Ip Holdings Llc Spirociklusos vegyületek
SG10202101055VA (en) * 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
AR110988A1 (es) * 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
JP2022092387A (ja) * 2020-12-10 2022-06-22 キヤノン株式会社 画像形成装置

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186883A (zh) * 2008-09-18 2011-09-14 诺雷克斯股份有限公司 Nmda受体调节剂和其用途
CN102933226A (zh) * 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
CN105026401A (zh) * 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105229010A (zh) * 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105229011A (zh) * 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105308049A (zh) * 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN105408336A (zh) * 2013-01-29 2016-03-16 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2017201285A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US20180092879A1 (en) * 2016-05-19 2018-04-05 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109415372A (zh) * 2016-05-19 2019-03-01 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIEL PETTERSEN 等: "Synthesis of enantiopure 5.7-spirodiamines: (S)-1,7-diaza[4.6]undecane and related compounds", 《TETRAHEDRON: ASYMMETRY》 *
JIA-QI LI 等: "Highly Enantioselective Iridium-Catalyzed Hydrogenation of a, b -Unsaturated Esters", 《CHEM. EUR. J.》 *

Also Published As

Publication number Publication date
AU2019215049A1 (en) 2020-09-17
IL276330A (en) 2020-09-30
EP3746442A1 (en) 2020-12-09
PH12020551140A1 (en) 2021-05-31
BR112020015666A2 (pt) 2021-02-23
WO2019152678A1 (en) 2019-08-08
CA3089559A1 (en) 2019-08-08
SG11202007251XA (en) 2020-08-28
PE20211455A1 (es) 2021-08-05
MX2020008106A (es) 2020-09-25
CL2020001990A1 (es) 2021-03-26
KR20200115610A (ko) 2020-10-07
JP2024019396A (ja) 2024-02-09
US20210047324A1 (en) 2021-02-18
JP2021512109A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
CN112218866A (zh) 螺-内酰胺nmda受体调节剂及其用途
EP2951185B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
JP7448747B2 (ja) スピロ－ラクタムｎｍｄａ修飾因子及びこれを用いた方法
CN105408336B (zh) 螺-内酰胺nmda受体调节剂及其用途
US10253032B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
CN105229011B (zh) 螺‑内酰胺nmda受体调节剂及其用途
EP3490994B1 (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
JP7210599B2 (ja) スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
CN109890825B (zh) 螺-内酰胺nmda受体调节剂及其用途
CN109937204B (zh) 螺-内酰胺nmda受体调节剂及其用途
CN105229010A (zh) 螺-内酰胺nmda受体调节剂及其用途
WO2019152685A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
WO2019152688A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2019152696A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2019152681A1 (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
WO2024054919A1 (en) Spiro-lactam nmda receptor modulators and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231220

Address after: Sheung Wan, Hongkong, China

Applicant after: Yuanyi Biotechnology (Hong Kong) Ltd.

Address before: Illinois, US

Applicant before: Aptinyx Inc.

AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20240927